A Series B project was sold for 15 billion yuan.
Right after securing a huge round of financing, a buyer came knocking.
Not long ago, Johnson & Johnson announced that it had signed an acquisition agreement with U.S. biotechnology firm Ollin Biosciences, with an upfront payment of 2.2 billion U.S. dollars, equivalent to about 15 billion yuan; there are also milestone payments of up to approximately 1.125 billion U.S. dollars tied to regulatory and commercial achievements, bringing the total maximum consideration to around 3.325 billion U.S. dollars. The announcement estimates that the transaction will be completed by the end of 2026, subject to regulatory approvals and satisfaction of customary closing conditions.
Five months prior to this acquisition, Ollin had just announced the completion of a 330 million U.S. dollars Series B financing. At that time, the round was co-led by ARCH and TCGX, with participation from institutions including a16z Bio+Health, BlackRock Multi-Asset Investments, and the Canada Pension Plan Investment Board. The raised funds will be used to advance the global Phase III clinical development of its core drug.
A company founded in 2023 has secured an acquisition agreement from a major pharmaceutical player right after reaching the Series B stage.
It is worth noting that there is a Chinese connection in this story: the core drug OLN324 that Johnson & Johnson is targeting was originally developed by Innovent Biologics. Its R&D code at Innovent is IBI324, before it was later licensed to Ollin for further development.
From the lab of a Chinese pharmaceutical enterprise, to an overseas biotechnology company, and then onto the M&A list of a multinational pharmaceutical giant, this drug that has not yet been approved for marketing has gone through several rounds of value assessment.
After Series B, Johnson & Johnson stepped in
Ollin made its public debut with both drug assets and sufficient capital in hand.
In September 2025, the company announced its official launch and disclosed an initial 100 million U.S. dollars financing, led by ARCH, Mubadala Capital and Monograph Capital. At that time, the enrollment for the U.S. Phase Ib head-to-head study of its core drug OLN324 had been completed, and another ophthalmic bispecific antibody had also entered the company's pipeline. It was only about 14 months from that point to the recent acquisition announcement, but the company's preparation started much earlier. As disclosed by Ollin, ARCH has been involved in its incubation together with Mubadala and Monograph since 2023. Paul Burns, Managing Director of ARCH, is also the co-founder and Executive Chairman of Ollin.
This means that investors started their work as early as the company was being set up.
Ollin positions itself as a drug asset-focused enterprise dedicated to in-licensing and developing ophthalmic therapies. It selects candidate drugs built on proven biological mechanisms, and then designs clinical development pathways around specific diseases. Compared with the lengthy early discovery phase, this model concentrates the company's main task on how to fully develop the drugs in its pipeline.
The supporting team is also highly targeted. Jason Ehrlich, Co-founder and CEO, previously served as Global Head of Clinical Ophthalmology at Genentech, and later as Chief Medical Officer and Chief Development Officer at Kodiak Sciences. During his tenure at Genentech, he participated in the development of ranibizumab, and also drove faricimab into global Phase III development. Later, faricimab precisely became the head-to-head comparator of Ollin's core drug. The development experience Ehrlich is familiar with has been directly put to use in the new company.
In June 2026, Ollin completed a 330 million U.S. dollars Series B financing, co-led by new investor TCGX and founding investor ARCH. In addition to institutions such as a16z and BlackRock, RA Capital and accounts advised by T. Rowe Price Investment Management also participated in the round, while Mubadala Capital and Monograph continued to invest.
This round of capital has clear designated uses. The company has obtained results from early randomized controlled trials, and completed the end-of-Phase II meeting with the U.S. Food and Drug Administration. The next step is to advance the global Phase III study. As development tasks become heavier, the company has also introduced capital from a wider range of institutional investors.
With clinical data released, follow-on financing secured, and then taken over by an industrial buyer, Ollin's rapid progress is clearly demonstrated. ARCH has participated in the whole process from incubation and initial financing all the way to Series B, integrating company building and consecutive investment in the same project.
However, the gap between the financing amount and the acquisition price cannot be directly regarded as the return of the fund. The total publicly disclosed financing of the two rounds amounts to 430 million U.S. dollars, which is the capital raised by the company; the entry valuation, shareholding ratio and distribution arrangement of each institution still need to be calculated separately. The actual cash the fund receives also depends on the closing result and the realization of subsequent milestones.
Johnson & Johnson has set its sights on this ophthalmic drug
When the financing reaches Series B, the drug has already moved to the Phase III stage. For the 15 billion yuan valuation of Ollin, these two progress milestones need to be viewed separately.
OLN324 targets wet age-related macular degeneration and diabetic macular edema. Both types of diseases involve abnormal fundus blood vessels and fluid leakage, which threaten patients' vision. For treatment, controlling retinal fluid is a key task, and how long the efficacy can last also affects the frequency of treatment that patients receive.
OLN324 is a bispecific antibody that targets both VEGF and Ang2. There are already commercialized products for this same target combination, which is faricimab from Roche, with the brand name Vabysmo. Roche disclosed that the product generated global sales of about 4.1 billion Swiss francs in 2025, making it one of its important revenue sources.
This market already has mature products, but there is still room for further improvement of therapeutic effects. Latecomers need to clarify what advantages their drugs actually have.
Ollin chose to conduct a direct comparison. Its JADE study recruited 164 patients in the U.S. to conduct a head-to-head evaluation of OLN324 and faricimab. Patients initially received three monthly administrations, followed by continuous follow-up, and could receive retreatment when the disease recurrence conditions specified in the protocol were met.
According to the final results announced by both parties in March 2026, among patients with diabetic macular edema, OLN324 showed more sufficient retinal drying, and the 4mg group also had numerically greater visual acuity improvement; among patients with wet age-related macular degeneration, the two drugs had similar retinal drying effects, but OLN324 showed a greater degree of improvement in the imaging indicator of pigment epithelial detachment thickness.
The data provides the basis for further development, and also sets the judgment boundary. This is a Phase Ib study, whose main objective is to evaluate safety and tolerability, while efficacy is a pre-set exploratory evaluation. "Numerically better" cannot be equated with proven statistically superior visual acuity improvement, let alone directly deduce the future market share.
For potential buyers, such studies still have value. Comparing a candidate drug with a marketed product in the same study helps to observe where the differences come from, and also gives subsequent Phase III development a more specific verification direction. The stronger and more durable disease control potential mentioned in Johnson & Johnson's announcement is built on the drug design and existing data.
As of November 16, Innovent disclosed that the relevant global Phase III trial has already started patient recruitment.
The timing of Johnson & Johnson's move is therefore worthy of attention. At this point, OLN324 already has clinical data available for evaluation, while key verification is still ahead. Johnson & Johnson plans to include it in its ophthalmology pipeline, use its own development and commercialization capabilities to continue advancing the program, and acquire a candidate asset in advance for future competition.
The consideration arrangement also reflects this phased feature. The 2.2 billion U.S. dollars upfront payment corresponds to the current acquisition commitment, while the subsequent maximum of about 1.125 billion U.S. dollars is tied to regulatory and commercial milestones. Whether the seller can receive the full amount depends on the subsequent progress of the drug.
Ollin has obtained a high offer, but there are still clinical issues that need to be further verified. The buyer and seller reached a transaction at the Phase III stage, and the arrangement of upfront payment plus milestone payments links part of the transaction consideration to the subsequent performance of the drug.
A Chinese drug entering the global M&A chain
Tracing back from OLN324, Innovent's role is deeper than just an "original developer".
Its 2025 annual report discloses that according to the agreement for IBI324 and Ollin, Innovent received an upfront payment and equity in Ollin, and is entitled to receive development, regulatory and commercial milestone payments, as well as tiered royalties on net sales.
In addition to licensing, Innovent also retains the possibility of participating in the company's value growth. How this equity will be handled after Ollin is acquired will affect Innovent's final proceeds. The currently disclosed information is not sufficient to calculate how much acquisition payment it can get, and the shareholding ratio and specific distribution arrangement still need further information for support.
This reflects the common cooperation idea in the NewCo model: set up an overseas company around the in-licensed drug, with a professional team responsible for development and institutional investors providing capital, while the original developer participates in the cooperation through cash, equity and other methods; when the drug advances to a new stage, the company will then obtain valuation from an industrial buyer.
Ollin's growth proves that the intermediate development work has concrete content. After obtaining the drug, it is necessary to organize clinical research, communicate with regulatory authorities, and gradually form evidence that can support the next stage of investment. The R&D results provided by Innovent and the development experience of Ollin's team are connected with each other along this path.
However, how much work each party has undertaken and how much value appreciation they can finally share needs to be referred back to the contract and execution results. An acquisition can demonstrate the buyer's recognition of the asset, but it cannot calculate the returns for all participants yet.
In addition to the acquisition agreement, another R&D funding arrangement has also been finalized.
On the same day Johnson & Johnson announced the acquisition, Blackstone Life Sciences disclosed a 750 million U.S. dollars development financing arrangement. After the acquisition is completed, Blackstone will provide capital to Johnson & Johnson to support the Phase III clinical development of OLN324. In return, Blackstone will be eligible to receive specified regulatory and sales milestone payments, as well as single-digit percentage sales royalties.
According to Johnson & Johnson's announcement, this fund will be paid over multiple years to fully finance the Phase III development of OLN324. It is two separate arrangements from the acquisition consideration, and cannot be added together as the selling price of Ollin. The role distinction here is also very clear: the participant in the Series B round is BlackRock Multi-Asset Investments, while the party providing the development fund this time is Blackstone Life Sciences. Equity investment and R&D financing intervene in different stages of the company and the product respectively, corresponding to different return mechanisms.
As a result, the subsequent development of this drug has formed a more detailed division of labor. Johnson & Johnson plans to acquire the company through the acquisition to continue advancing the candidate drug; Blackstone supports the Phase III R&D through a dedicated financing arrangement and participates in future returns. Even after the transaction is closed, professional capital will still remain in the drug development process.
For Chinese innovative pharmaceutical enterprises, Ollin provides a sample worthy of tracking. Whether the cooperation partner has the ability to continue advancing the drug, and how to realize the equity and product rights retained at the time of licensing, will affect the final revenue that an R&D achievement can bring.
The 15 billion yuan upfront payment has brought this Series B company into the public view. Next, it remains to be seen whether the global Phase III study can support its clinical potential, and whether the participants on this cross-border cooperation chain can turn the rights and interests specified in the agreement into actual returns.
Author | Wang Tao Editor | Wu Ren
Source | Thecapital Finance
This article is from the WeChat official account "Thecapital Finance" (ID: thecapital), written by Wang Tao, authorized for release by 36Kr.